文献速递免疫规划传染病防控与疫情报告

甲肝与肠道病毒71型联合疫苗的临床前安全性评估

Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
PubMed 文献 · Vaccine · 2021-06-02

本研究在良好实验室规范条件下,用大鼠进行单次高剂量和重复高/低剂量毒性试验,并用豚鼠进行全身过敏试验,评估甲肝灭活疫苗与肠道病毒71型灭活疫苗联合疫苗的安全性。结果显示单次给药无异常,重复给药三剂后局部淋巴结可见巨噬细胞吞噬嗜碱性颗粒及注射部位刺激,但末次给药后56天淋巴结无明显组织病理学改变且局部刺激逐渐消退,豚鼠过敏试验未见过敏反应,提示该联合疫苗具有良好的安全性。

要点

  • 单次高剂量给药大鼠未见明显临床症状、体重异常或大体病理改变。
  • 重复三剂给药后局部淋巴结可见巨噬细胞吞噬嗜碱性颗粒及注射部位刺激,56天后消退。
  • 豚鼠全身过敏试验中联合疫苗未引发过敏反应,体重增长正常。

核心结论

  • 甲肝灭活疫苗与EV71灭活疫苗联合疫苗在临床前研究中显示出良好的安全性。

研究设计与样本

  • 在良好实验室规范条件下,用CD®(Sprague Dawley) IGS大鼠进行单次高剂量毒性试验和重复高/低剂量毒性试验,并用豚鼠进行全身过敏试验。

主要发现

  • 单次给药大鼠未见明显临床症状、体重异常及大体病理改变。
  • 重复三剂给药大鼠在腹股沟、肠系膜和局部淋巴结可见巨噬细胞吞噬嗜碱性颗粒,并伴有给药部位刺激。
  • 末次给药后56天淋巴结未见明显组织病理学改变,局部刺激逐渐消退。
  • 豚鼠经全身致敏和激发后体重增长正常,未见过敏反应。

临床怎么用

  • 该临床前安全性数据可为联合疫苗后续临床研究和应用提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since 2007, Hepatitis A (HAV) vaccination has been a part of the National Immunization Program of China. Recognizing enterovirus 71 (EV71) as the most important pathogen in severe hand, foot and mouth disease, an inactivated EV71 vaccine was successfully marketed in 2015. Based on the concept of one vaccine preventing two diseases and owing to similarities in vaccine preparation and the overlap of the eligible population, a combination of the inactivated HAV vaccine and inactivated EV71 vaccine is theoretically feasible and desirable. However, the optimal vaccinationschedule for this combination vaccine has yet to be optimized. Use of this combined vaccine would not only decrease the number of vaccinations, but also lower associated cost. This study aimed to investigate the toxicity and adverse reactions of the combined HAV-EV71 vaccine under Good Laboratory Practice conditions to provide a reference for clinical studies/applications in the future. CD®(Sprague Dawley) IGS rats were employed for single-dose toxicity testing using a high dose, and repeated-dose toxicity testing using high, as well as low doses. Animals that received only a single dose showed no obvious clinical symptoms nor abnormal body weight, and no significant gross pathological change at the experimental endpoint at necropsy. In the rats injected with three doses, phagocytosis of basophilic granules by macrophages was observed in the inguinal, mesenteric, and local lymph nodes, besides irritation at the administration site. At 56 days after the last dose, no significant histopathological change was observed in the lymph nodes, and local irritation gradually faded. Further, systematic allergy testing was performed in guinea pigs. After systemic sensitization and challenge with the HAV-EV71 vaccine, animals showed normal weight gain and no allergic reactions. This study, therefore, confirmed a good safety profile of the inactivated HAV and EV71 combined vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yang T, Liu B, Yue L, et al. Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71. Vaccine. 2021. PMID: 34088510. doi:10.1016/j.vaccine.2021.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。